These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 32876735)
1. Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma. Yang H; Sun L; Guan A; Yin H; Liu M; Mao X; Xu H; Zhao H; Lu X; Sang X; Zhong S; Chen Q; Mao Y Cancer Immunol Immunother; 2021 Mar; 70(3):667-677. PubMed ID: 32876735 [TBL] [Abstract][Full Text] [Related]
2. TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration. Jiang Y; Chen S; Li Q; Liang J; Lin W; Li J; Liu Z; Wen M; Cao M; Hong J Front Immunol; 2021; 12():612139. PubMed ID: 33679751 [TBL] [Abstract][Full Text] [Related]
3. Identification of WDFY3 Neoantigens as Prognostic Markers in Longterm Survivors of Extrahepatic Cholangiocarcinoma. Wang Y; Jin B; Zhou N; Sun Z; Li J; Chen Q; Wu X; Zhou Y; Shi Y; Lu X; Sang X; Mao Y; Du S; Wang W; Bai C Curr Cancer Drug Targets; 2020; 20(11):875-886. PubMed ID: 32957886 [TBL] [Abstract][Full Text] [Related]
4. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. Long J; Wang A; Bai Y; Lin J; Yang X; Wang D; Yang X; Jiang Y; Zhao H EBioMedicine; 2019 Apr; 42():363-374. PubMed ID: 30885723 [TBL] [Abstract][Full Text] [Related]
5. Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma. Liu T; Wu H; Qi J; Qin C; Zhu Q Cancer Med; 2020 Oct; 9(20):7440-7452. PubMed ID: 32815653 [TBL] [Abstract][Full Text] [Related]
6. Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma. Ye C; Lin S; Hong J; Liu F; Guo G; Chen S; Zhou Z; Lin W; Li J; Ye Y Eur J Immunol; 2023 May; 53(5):e2250054. PubMed ID: 36794567 [TBL] [Abstract][Full Text] [Related]
7. The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. Linxweiler M; Kuo F; Katabi N; Lee M; Nadeem Z; Dalin MG; Makarov V; Chowell D; Dogan S; Ganly I; Hakimi AA; Wong RJ; Riaz N; Ho AL; Chan TA; Morris LGT Clin Cancer Res; 2020 Jun; 26(12):2859-2870. PubMed ID: 32060100 [TBL] [Abstract][Full Text] [Related]
8. Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer. Yang H; Yu M; Zhong S; You Y; Feng F J Ovarian Res; 2022 Jan; 15(1):18. PubMed ID: 35093146 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations. Li W; Wu H; Xu X; Zhang Y Aging (Albany NY); 2021 Apr; 13(8):11564-11594. PubMed ID: 33867349 [TBL] [Abstract][Full Text] [Related]
10. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370 [TBL] [Abstract][Full Text] [Related]
11. Expression, immune infiltration and clinical significance of SPAG5 in hepatocellular carcinoma: A gene expression-based study. Chen W; Chen X; Li S; Ren B J Gene Med; 2020 Apr; 22(4):e3155. PubMed ID: 31860771 [TBL] [Abstract][Full Text] [Related]
12. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Balachandran VP; Łuksza M; Zhao JN; Makarov V; Moral JA; Remark R; Herbst B; Askan G; Bhanot U; Senbabaoglu Y; Wells DK; Cary CIO; Grbovic-Huezo O; Attiyeh M; Medina B; Zhang J; Loo J; Saglimbeni J; Abu-Akeel M; Zappasodi R; Riaz N; Smoragiewicz M; Kelley ZL; Basturk O; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Gönen M; Levine AJ; Allen PJ; Fearon DT; Merad M; Gnjatic S; Iacobuzio-Donahue CA; Wolchok JD; DeMatteo RP; Chan TA; Greenbaum BD; Merghoub T; Leach SD Nature; 2017 Nov; 551(7681):512-516. PubMed ID: 29132146 [TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data. Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866 [TBL] [Abstract][Full Text] [Related]
14. Prognostic evaluation and immune infiltration analysis of five bioinformatic selected genes in hepatocellular carcinoma. Lai E; Tai Y; Jiang J; Zhao C; Xiao Y; Quan X; Wu H; Gao J J Cell Mol Med; 2021 Dec; 25(24):11128-11141. PubMed ID: 34726341 [TBL] [Abstract][Full Text] [Related]
16. Neoantigen Fitness Model Predicts Lower Immune Recognition of Cutaneous Squamous Cell Carcinomas Than Actinic Keratoses. Borden ES; Kang P; Natri HM; Phung TN; Wilson MA; Buetow KH; Hastings KT Front Immunol; 2019; 10():2799. PubMed ID: 31849976 [TBL] [Abstract][Full Text] [Related]
17. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma. Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y Front Immunol; 2021; 12():719175. PubMed ID: 34603293 [TBL] [Abstract][Full Text] [Related]
18. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer. Manzano RG; Catalan-Latorre A; Brugarolas A BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103 [TBL] [Abstract][Full Text] [Related]
19. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506 [No Abstract] [Full Text] [Related]
20. Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma. Nejo T; Matsushita H; Karasaki T; Nomura M; Saito K; Tanaka S; Takayanagi S; Hana T; Takahashi S; Kitagawa Y; Koike T; Kobayashi Y; Nagae G; Yamamoto S; Ueda H; Tatsuno K; Narita Y; Nagane M; Ueki K; Nishikawa R; Aburatani H; Mukasa A; Saito N; Kakimi K Cancer Immunol Res; 2019 Jul; 7(7):1148-1161. PubMed ID: 31088845 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]